Open AccessP686: A PHASE 1 FIRST IN‐HUMAN STUDY OF BGB‐16673, A BRUTON TYROSINE KINASE PROTEIN DEGRADER, IN PATIENTS (PTS) WITH B‐CELL MALIGNANCIES (TRIAL IN PROGRESS)
Author(s) -
Tam C. S.,
Cheah C.,
Stevens D. A.,
By K.,
Chen X.,
Tariq B.,
Vosganian G. S.,
Huang J.,
Alwan M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845628.43637.11
Subject(s) - bruton's tyrosine kinase , ibrutinib , chronic lymphocytic leukemia , tolerability , medicine , cancer research , b cell receptor , mantle cell lymphoma , breakpoint cluster region , b cell , lymphoma , tyrosine kinase , oncology , pharmacology , leukemia , immunology , adverse effect , antibody , receptor